Latest Breaking News On - Base holding - Page 5 : comparemela.com

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis News provided by Share this article STOCKHOLM, April 12, 2021 /PRNewswire/ SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase s strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms. The study is from the Swiss institute of Allergy and Asthma Research (SIAF) and has been published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin. The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.

United statesSwitzerland generalCezmi akdisSimon grantLife science zurich graduate schoolAllergy researchAsthma researchSwiss institute of allergySwiss research institutes for high altitude climateScibase holdingPrnewswire scibase holding abEuropean academy of allergyUniversity of zurichEuropean journalClinical immunologyDirector cezmi akdis